Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Dow
Express Scripts
AstraZeneca
Merck

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Argininosuccinate

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Argininosuccinate?

Argininosuccinate is an investigational drug.

There have been 4 clinical trials for Argininosuccinate. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are Sarcoma, Mesothelioma, and Wounds and Injuries. The leading clinical trial sponsors are Polaris Group, Washington University School of Medicine, and Polaris Pharmaceuticals, Inc.

There are eighty-seven US patents protecting this investigational drug and four hundred and eighty-four international patents.

Recent Clinical Trials for Argininosuccinate
TitleSponsorPhase
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue SarcomaPolaris Pharmaceuticals, Inc.Phase 2
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue SarcomaWashington University School of MedicinePhase 2
Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and CisplatinPolaris GroupPhase 2/Phase 3

See all Argininosuccinate clinical trials

Clinical Trial Summary for Argininosuccinate

Top disease conditions for Argininosuccinate
Top clinical trial sponsors for Argininosuccinate

See all Argininosuccinate clinical trials

US Patents for Argininosuccinate

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Argininosuccinate   Start Trial Methods of evaluating patients using E-cadherin or vimentin Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Argininosuccinate   Start Trial Graphite electrode comprising electrochemically reduced graphene oxide and methods thereof KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (Dhahran, SA)   Start Trial
Argininosuccinate   Start Trial Methods of therapeutic monitoring of nitrogen scavenging drugs Horizon Therapeutics, LLC (Lake Forest, IL)   Start Trial
Argininosuccinate   Start Trial Methods of therapeutic monitoring of nitrogen scavenging drugs Horizon Therapeutics, LLC (Lake Forest, IL)   Start Trial
Argininosuccinate   Start Trial Methods of therapeutic monitoring of nitrogen scavenging drugs Horizon Therapeutics, LLC (Lake Forest, IL)   Start Trial
Argininosuccinate   Start Trial Methods of therapeutic monitoring of nitrogen scavenging drugs Horizon Therapeutics, LLC (Lake Forest, IL)   Start Trial
Argininosuccinate   Start Trial Methods of therapeutic monitoring of nitrogen scavenging drugs Horizon Therapeutics, LLC (Lake Forest, IL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Argininosuccinate

Drugname Country Document Number Estimated Expiration Related US Patent
Argininosuccinate European Patent Office 2895623 2032-09-17   Start Trial
Argininosuccinate Spain 2690829 2032-09-17   Start Trial
Argininosuccinate World Intellectual Property Organization (WIPO) 2014043633 2032-09-17   Start Trial
Argininosuccinate Australia 2012316750 2031-09-30   Start Trial
Argininosuccinate Australia 2017251691 2031-09-30   Start Trial
Argininosuccinate Brazil 112014007357 2031-09-30   Start Trial
Argininosuccinate Canada 2850391 2031-09-30   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Medtronic
Express Scripts
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.